Global Biosimilar Drugs Market Analysis 2016 - Forecast to 2022

Description: The report contains up to date financial data derived from varied research sources to present unique and reliable analysis. Assessment of major trends with potential impact on the market during the next five years, including a deep dive analysis of market segmentation which comprises of sub markets, regional and country level analysis. The report provides a comprehensive outlook about the market share along with strategic recommendations based on the emerging segments.

This report analyzes the global markets for "Biosimilar Drugs". The market assessment is performed through standard and the tailored research methodology approach. The market overview offers in depth analysis at the regional and country level, for instance North America (U.S., Canada and Mexico), Europe (Germany, France, Italy, U.K. and Spain), Asia-Pacific (China, Japan, India, Australia, South Korea and Rest of APAC) and Rest of the World (Middle East, Africa and Latin America). Annual estimations and forecasts are provided from the year 2013 to 2022 for each given segment and sub segments. Market data derived from the authenticated and reliable sources is subjected to validation from the industry experts. The report also analyzes the market by discussing market dynamics such as drivers, constraints, opportunities, threats, challenges and other market trends.

Competitive landscaping provides the recent activities performed by the active players in the market. Activities such as product launch, agreements, joint ventures, partnerships, acquisitions and mergers, and other activities.

This report provides:
- Market Sizing estimations and forecasts for 6 years across the given market segments
- Identifying market dynamics (Drivers, Restraints, Opportunities, Threats, Challenges and Opportunities, )
- Strategic recommendations in key business segments based on the market estimations
- Regional and country level market analysis
- Competitive landscaping of major market players
- Company profiling covering the financials, recent activities and the future strategies

Contents:
1 Introduction
1.1 Scope of the Report
1.2 Report Description
1.3 Research Methodology
1.4 Research Sources
1.4.1 Primary Research Sources
1.4.2 Secondary Research Sources
1.4.3 Assumptions
1.5 List of Abbreviations

2 Executive Summary

3 Market Analysis
3.1 Market Segmentation
3.2 Market Size Estimation
3.3 Market Drivers
3.4 Market Constraints

4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Biosimilar drugs Market by Drug Class
5.1 Introduction
5.2 Erythropoietin (EPO)
5.3 FC-Fusion Proteins
5.4 Gonadotropins (Glycoprotein Hormones)
5.5 Granulocyte Colony-Stimulating Factor (Filgrastim)
5.6 Human Growth Hormone (HGH)
5.7 Insulin
5.8 Interferons
5.9 Monoclonal Antibodies (MABS)
5.10 Other Drugs

6 Biosimilar drugs Market by Manufacturing Type
6.1 Introduction
6.2 Contract Manufacturing
6.3 In-House Manufacturing

7 Biosimilar drugs Market by Application
7.1 Introduction
7.2 Blood Disorders
7.3 Chronic and Autoimmune Diseases
7.4 Growth Hormone Deficiency
7.5 Infectious Diseases
7.6 Oncology
7.7 Other Applications

8 Geographical Segmentation
8.1 North America
8.1.1 US
8.1.2 Canada
8.1.3 Mexico
8.2 Europe
8.2.1 Germany
8.2.2 France
8.2.3 Italy
8.2.4 Spain
8.2.5 UK
8.3 Asia Pacific
8.3.1 Japan
8.3.2 China
8.3.3 India
8.3.4 Australia
8.3.5 South Korea
8.3.6 Rest of Asia Pacific
8.4 Rest of the World
8.4.1 Latin America
8.4.2 Middle East
8.4.3 Africa
8.4.4 Others

9 Vendor Landscaping
9.1 Agreements, Partnerships, Collaborations and Joint Ventures
9.2 Acquisitions & Mergers
9.3 New Product Launch
9.4 Expansions
9.5 Other Key Strategies

10 Company Profiles
10.1 Abbott Laboratories
10.1.1 Business Overview
10.1.2 SWOT Analysis
10.1.3 Financial Overview
10.1.4 Strategy
10.1.5 Key Activities
10.2 AET BioTech
10.3 Baxter International
10.4 Bayer
10.5 Becton, Dickinson and Company
10.6 Boehringer Ingelheim
10.7 Celgene Corporation
10.8 Cipla
10.9 Covidien
10.10 Dr. Reddy’s Laboratories
10.11 Fujifilm Corporation
10.12 Johnson & Johnson
10.13 Kowa Company
10.14 LG Life Sciences
10.15 Merck and Co.
10.16 Pfizer Inc.
10.17 Mylan Inc.
10.18 F. Hoffmann-La Roche Ltd.
10.19 Novartis
10.20 Samsung Bioepis
10.21 Teva Pharmaceutical Industries Ltd.

11 Appendix

12 Disclaimer

List of Tables

Table 1 Global Biosimilar drugs Market Analysis, by Region, 2013-2022 ($MN)
Table 2 Global Biosimilar drugs Market Analysis, by Drug Class, 2013-2022 ($MN)
Table 3 Global Erythropoietin (EPO) Market Analysis, by Region, 2013-2022 ($MN)
Table 4 Global FC-Fusion Proteins Market Analysis, by Region, 2013-2022 ($MN)
Table 5 Global Gonadotropins (Glycoprotein Hormones) Market Analysis, by Region, 2013-2022 ($MN)
Table 6 Global Granulocyte Colony-Stimulating Factor (Filgrastim) Market Analysis, by Region, 2013-2022 ($MN)
Table 7 Global Human Growth Hormone (HGH) Market Analysis, by Region, 2013-2022 ($MN)
Table 8 Global Insulin Market Analysis, by Region, 2013-2022 ($MN)
Table 9 Global Interferons Market Analysis, by Region, 2013-2022 ($MN)
Table 10 Global Monoclonal Antibodies (MABS) Market Analysis, by Region, 2013-2022 ($MN)
Table 11 Global Other Drugs Market Analysis, by Region, 2013-2022 ($MN)
Table 12 Global Biosimilar drugs Market Analysis, by Manufacturing Type, 2013-2022 ($MN)
Table 13 Global Contract Manufacturing Market Analysis, by Region, 2013-2022 ($MN)
Table 14 Global In-House Manufacturing Market Analysis, by Region, 2013-2022 ($MN)
Table 15 Global Biosimilar drugs Market Analysis, by Application, 2013-2022 ($MN)
Table 16 Global Blood Disorders Market Analysis, by Region, 2013-2022 ($MN)
Table 17 Global Chronic and Autoimmune Diseases Market Analysis, by Region, 2013-2022 ($MN)
Table 18 Global Growth Hormone Deficiency Market Analysis, by Region, 2013-2022 ($MN)
Table 19 Global Infectious Diseases Market Analysis, by Region, 2013-2022 ($MN)
Table 20 Global Oncology Market Analysis, by Region, 2013-2022 ($MN)
Table 21 Global Other Applications Market Analysis, by Region, 2013-2022 ($MN)
Table 22 North America Biosimilar drugs Market Analysis, by Country, 2013-2022 ($MN)
Table 23 North America Biosimilar drugs Market Analysis, by Drug Class, 2013-2022 ($MN)
Table 24 North America Erythropoietin (EPO) Market Analysis, by Country, 2013-2022 ($MN)
Table 25 North America FC-Fusion Proteins Market Analysis, by Country, 2013-2022 ($MN)
Table 26 North America Gonadotropins (Glycoprotein Hormones) Market Analysis, by Country, 2013-2022 ($MN)
Table 27 North America Granulocyte Colony-Stimulating Factor (Filgrastim) Market Analysis, by Country, 2013-2022 ($MN)
Table 29 North America Insulin Market Analysis, by Country, 2013-2022 ($MN)
Table 30 North America Interferons Market Analysis, by Country, 2013-2022 ($MN)
Table 31 North America Monoclonal Antibodies (MABS) Market Analysis, by Country, 2013-2022 ($MN)
Table 32 North America Other Drugs Market Analysis, by Country, 2013-2022 ($MN)
Table 33 North America Biosimilar drugs Market Analysis, by Manufacturing Type, 2013-2022 ($MN)
Table 34 North America Contract Manufacturing Market Analysis, by Country, 2013-2022 ($MN)
Table 35 North America In-House Manufacturing Market Analysis, by Country, 2013-2022 ($MN)
Table 36 North America Biosimilar drugs Market Analysis, by Application, 2013-2022 ($MN)
Table 37 North America Blood Disorders Market Analysis, by Country, 2013-2022 ($MN)
Table 38 North America Chronic and Autoimmune Diseases Market Analysis, by Country, 2013-2022 ($MN)
Table 39 North America Growth Hormone Deficiency Market Analysis, by Country, 2013-2022 ($MN)
Table 40 North America Infectious Diseases Market Analysis, by Country, 2013-2022 ($MN)
Table 41 North America Oncology Market Analysis, by Country, 2013-2022 ($MN)
Table 42 North America Other Applications Market Analysis, by Country, 2013-2022 ($MN)
Table 43 Europe Biosimilar drugs Market Analysis, by Country, 2013-2022 ($MN)
Table 44 Europe Biosimilar drugs Market Analysis, by Drug Class, 2013-2022 ($MN)
Table 45 Europe Erythropoietin (EPO) Market Analysis, by Country, 2013-2022 ($MN)
Table 46 Europe FC-Fusion Proteins Market Analysis, by Country, 2013-2022 ($MN)
Table 47 Europe Gonadotropins (Glycoprotein Hormones) Market Analysis, by Country, 2013-2022 ($MN)
Table 48 Europe Granulocyte Colony-Stimulating Factor (Filgrastim) Market Analysis, by Country, 2013-2022 ($MN)
Table 49 Europe Human Growth Hormone (HGH) Market Analysis, by Country, 2013-2022 ($MN)
Table 50 Europe Insulin Market Analysis, by Country, 2013-2022 ($MN)
Table 51 Europe Interferons Market Analysis, by Country, 2013-2022 ($MN)
Table 52 Europe Monoclonal Antibodies (MABS) Market Analysis, by Country, 2013-2022 ($MN)
Table 53 Europe Other Drugs Market Analysis, by Country, 2013-2022 ($MN)
Table 54 Europe Biosimilar drugs Market Analysis, by Manufacturing Type, 2013-2022 ($MN)
Table 55 Europe Contract Manufacturing Market Analysis, by Country, 2013-2022 ($MN)
Table 56 Europe In-House Manufacturing Market Analysis, by Country, 2013-2022 ($MN)
Table 57 Europe Biosimilar drugs Market Analysis, by Application, 2013-2022 ($MN)
Table 58 Europe Blood Disorders Market Analysis, by Country, 2013-2022 ($MN)
Table 59 Europe Chronic and Autoimmune Diseases Market Analysis, by Country, 2013-2022 ($MN)
Table 60 Europe Growth Hormone Deficiency Market Analysis, by Country, 2013-2022 ($MN)
Table 61 Europe Infectious Diseases Market Analysis, by Country, 2013-2022 ($MN)
Table 62 Europe Oncology Market Analysis, by Country, 2013-2022 ($MN)
Table 63 Europe Other Applications Market Analysis, by Country, 2013-2022 ($MN)
Table 64 Asia Pacific Biosimilar drugs Market Analysis, by Country, 2013-2022 ($MN)
Table 65 Asia Pacific Biosimilar drugs Market Analysis, by Drug Class, 2013-2022 ($MN)
Table 66 Asia Pacific Erythropoietin (EPO) Market Analysis, by Country, 2013-2022 ($MN)
Table 67 Asia Pacific FC-Fusion Proteins Market Analysis, by Country, 2013-2022 ($MN)
Table 68 Asia Pacific Gonadotropins (Glycoprotein Hormones) Market Analysis, by Country, 2013-2022 ($MN)
Table 69 Asia Pacific Granulocyte Colony-Stimulating Factor (Filgrastim) Market Analysis, by Country, 2013-2022 ($MN)
Table 70 Asia Pacific Human Growth Hormone (HGH) Market Analysis, by Country, 2013-2022 ($MN)
Table 71 Asia Pacific Insulin Market Analysis, by Country, 2013-2022 ($MN)
Table 72 Asia Pacific Interferons Market Analysis, by Country, 2013-2022 ($MN)
Table 73 Asia Pacific Monoclonal Antibodies (MABS) Market Analysis, by Country, 2013-2022 ($MN)
Table 74 Asia Pacific Other Drugs Market Analysis, by Country, 2013-2022 ($MN)
Table 75 Asia Pacific Biosimilar drugs Market Analysis, by Manufacturing Type, 2013-2022 ($MN)
Table 76 Asia Pacific Contract Manufacturing Market Analysis, by Country, 2013-2022 ($MN)
Table 77 Asia Pacific In-House Manufacturing Market Analysis, by Country, 2013-2022 ($MN)
Table 78 Asia Pacific Biosimilar drugs Market Analysis, by Application, 2013-2022 ($MN)
Table 79 Asia Pacific Blood Disorders Market Analysis, by Country, 2013-2022 ($MN)
Table 80 Asia Pacific Chronic and Autoimmune Diseases Market Analysis, by Country, 2013-2022 ($MN)
Table 81 Asia Pacific Growth Hormone Deficiency Market Analysis, by Country, 2013-2022 ($MN)
Table 82 Asia Pacific Infectious Diseases Market Analysis, by Country, 2013-2022 ($MN)
Table 83 Asia Pacific Oncology Market Analysis, by Country, 2013-2022 ($MN)
Table 84 Asia Pacific Other Applications Market Analysis, by Country, 2013-2022 ($MN)
Table 85 RoW Biosimilar drugs Market Analysis, by Country, 2013-2022 ($MN)
Table 86 RoW Biosimilar drugs Market Analysis, by Drug Class, 2013-2022 ($MN)
Table 87 RoW Erythropoietin (EPO) Market Analysis, by Country, 2013-2022 ($MN)
Table 88 RoW FC-Fusion Proteins Market Analysis, by Country, 2013-2022 ($MN)
Table 89 RoW Gonadotropins (Glycoprotein Hormones) Market Analysis, by Country, 2013-2022 ($MN)
Table 90 RoW Granulocyte Colony-Stimulating Factor (Filgrastim) Market Analysis, by Country, 2013-2022 ($MN)
Table 91 RoW Human Growth Hormone (HGH) Market Analysis, by Country, 2013-2022 ($MN)
Table 92 RoW Insulin Market Analysis, by Country, 2013-2022 ($MN)
Table 93 RoW Interferons Market Analysis, by Country, 2013-2022 ($MN)
Table 94 RoW Monoclonal Antibodies (MABS) Market Analysis, by Country, 2013-2022 ($MN)
Table 95 RoW Other Drugs Market Analysis, by Country, 2013-2022 ($MN)
Table 96 RoW Biosimilar drugs Market Analysis, by Manufacturing Type, 2013-2022 ($MN)
Table 97 RoW Contract Manufacturing Market Analysis, by Country, 2013-2022 ($MN)
Table 98 RoW In-House Manufacturing Market Analysis, by Country, 2013-2022 ($MN)
Table 99 RoW Biosimilar drugs Market Analysis, by Application, 2013-2022 ($MN)
Table 100 RoW Blood Disorders Market Analysis, by Country, 2013-2022 ($MN)
Table 101 RoW Chronic and Autoimmune Diseases Market Analysis, by Country, 2013-2022 ($MN)
Table 102 RoW Growth Hormone Deficiency Market Analysis, by Country, 2013-2022 ($MN)
Table 103 RoW Infectious Diseases Market Analysis, by Country, 2013-2022 ($MN)
Table 104 RoW Oncology Market Analysis, by Country, 2013-2022 ($MN)
Table 105 RoW Other Applications Market Analysis, by Country, 2013-2022 ($MN)

Ordering:

Order Online - [http://www.researchandmarkets.com/reports/4083448/](http://www.researchandmarkets.com/reports/4083448/)

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Global Biosimilar Drugs Market Analysis 2016 - Forecast to 2022
Web Address: http://www.researchandmarkets.com/reports/4083448/
Office Code: SC2GYG9C

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td></td>
<td>USD 4550</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td></td>
<td>USD 6150</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td></td>
<td>USD 7500</td>
</tr>
</tbody>
</table>

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: ____________________________ Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof [ ]
First Name: ____________________________ Last Name: ____________________________
Email Address: * ____________________________
Job Title: ____________________________
Organisation: ____________________________
Address: ____________________________
City: ____________________________
Postal / Zip Code: ____________________________
Country: ____________________________
Phone Number: ____________________________
Fax Number: ____________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information
Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB9853308313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World